Company: BLRX
Filing Date: 2025-01-07
Form Type: 424B5
Source: 0001178913-25-000045
Chunk: 25

Company: BioLineRx Ltd.
Filing Date: 2025-01-07
Form: 424B5
Chunk 25
---
 with respect to 
 ordinary shares and $0 to $0.42 with respect to ADSs;                                                                                                                                                                                    |

| • | 49,269,450 ordinary shares, represented by 3,284,630 ADSs, reserved for future issuance under the Share Incentive Plan; |

| • | 185,249,340 ordinary shares represented by 12,349,956 ADSs issuable upon exercise of pre-funded warrants issued in the November 2024 Registered Direct offering, at an exercise price of $0.0001 per ADS, of which 135,774,465 ordinary 
 shares represented by 9,051,631 ADSs were issued following the cashless exercise of such pre-funded warrants after September 30, 2024;                                                                                                  |

| • | 123,535,860 ordinary shares represented by 8,235,724 ADSs issuable upon exercise of warrants to be issued in the November 2024 Registered Direct Offering, at an exercise price of $0.5900 per ADS; |

| • | 235,018,170 ordinary shares represented by 15,667,878 ADSs issuable upon exercise of pre-funded warrants to be issued to the investors in this offering, at an exercise price of $0.0001 per ADS; |

| • | 750,000,000 ordinary shares represented by 50,000,000 ADSs issuable upon exercise of warrants to be issued to the investors in this offering, at an exercise price of $0.20 per ADS; and |

| • | 37,500,000 ordinary shares represented by 2,500,000 ADSs issuable upon exercise of warrants to be issued to the placement agent or its designees as compensation in connection with this offering, at an exercise price of $0.25 per ADS. |

To the extent that any of these outstanding options or warrants are exercised or we issue additional ADSs or ordinary shares under our equity incentive plans, there will be further dilution to new investors. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to new investors participating in this offering. USE OF PROCEEDS We estimate that the net proceeds received by us from this offering, after estimated offering expenses payable by us, will be approximately $8.9 million. These estimates exclude the proceeds, if any, from the exercise pre-funded warrants and warrants sold in this offering. If all of the pre-funded